Adalimumab Market Analysis - Forecast(2021 - 2026)

Report Code: HCR 0100 Report Format: PDF + Excel (Delivery in 48 Hrs)

Adalimumab Market Overview

Adalimumab Market size is estimated to reach $4.3 Billion by 2025 and is poised to grow at a CAGR of 4.98% during the forecast period 2020-2025. Adalimumab, with brand name of Humira and Exemptia, which is an anti-TNF medication used to treat rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Adalimumab is usually associated with tumor necrosis factor alpha (TNFα). When TNFα binds to the TBFα receptor, it produces an inflammatory response to autoimmune diseases. Adalimumab, by binding to TNFα, reduces the chances of an inflammatory response. The increasing incidence of acute arthritis and ulcerative colitis drives the adalimumab market. Owing to an unhealthy lifestyle adaptation, increased stress in daily life, dysfunction in the Immune system are factors which are estimated to boost the growth of the adalimumab market. However, the sedentary lifestyle of people all over the world which aids in increasing the prevalence of arthritis, which is projected to boost the global adalimumab market over the forecast years 2020-2025. 

Adalimumab Market Report Coverage

The report: “Adalimumab Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Adalimumab Market.
By Type: Adalimumab, Adalimumab Biosimilar.
By Disease: Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others.
By End-User: Hospitals, Specialty Clinics, and others.
By Geography: North America, Asia-Pacific, Europe, and Rest of World.

Key Takeaways

  • Geographically, the North America area is poised to see extraordinary development owing to the owing to the advanced healthcare infrastructure, reimbursement coverage and a well-regulated regulatory framework in the region and is set to continue during forecast period 2020-2025.
  • The global demand for the Adalimumab Market is owing to the rising incidences of arthritis around the globe. 
  • The high cost and the side effects caused by Adalimumab, which is estimated to restrain the market growth during the forecast period 2020-2025.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Adalimumab Market report.

Adalimumab Market Segment Analysis - By Disease

The global Adalimumab Market based on Mode of Disease, can be further segmented into Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others. Rheumatoid arthritis segment registered for the highest revenue in 2019 and is estimated to grow at highest CAGR over the forecast years 2020-2025. This is owing to the high prevalence of rheumatoid arthritis across the world. The introduction of new therapeutic agents and government support for high-cost treatment products are major factors driving the rheumatoid arthritis segment.

Adalimumab Market Segment Analysis - By End-User

The global Adalimumab Market based on Mode of End-Use, can be further segmented into Hospitals, Specialty Clinics, and others. The Hospitals segment registered for highest revenue in 2019 and projected to grow at the highest CAGR of 5.1% during the forecast period 2020-2025 owing to the growing number of patients suffering from arthritis and ulcerative colitis. However, the rising prevalence of Rheumatoid arthritis is the major reason for driving the segment.

Adalimumab Market Segment Analysis - By Geography

The global Adalimumab Market based on Geography, can be further segmented into North America, Asia-Pacific, Europe, and Rest of World. North America registered for the highest revenue share of 37.1% in 2019 owing to the advanced healthcare infrastructure, reimbursement coverage and a well-regulated regulatory framework in the region. However, Asia-Pacific is estimated to outpace all the regions by clocking the highest CAGR during the forecast period 2020-2025 owing to the factors such as rising disposable income, rapid development of healthcare infrastructure and municipal / governmental measures to improve the healthcare sector in the region.

Adalimumab Market Drivers

Rise in Demand

The global Adalimumab Market is driven by the high incidence of arthritis, which is among the main factors driving the market's growth. Women are more likely to develop osteoarthritis owing to calcium loss from the body compared to males, this is estimated to lead to an increased demand for adalimumab during the forecast period 2020-2025. Moreover, the sedentary lifestyle of people all over the world, which aids in increasing the prevalence of arthritis, which is projected to augment market demand over the forecast period 2020-2025.

Adalimumab Market Challenges

Side effects and high cost of Adalimumab

Common side effects of Adalimumab include redness, swelling, itching, rash, bleeding, bruising, and pain at the injection site. In addition, side effects such as upper respiratory infections (RTI), nausea, vomiting, anaphylaxis, hepatitis B infection, increased risk of heart failure, internal bleeding, psoriasis, headache, and, liver injury are some of the other side effects of adalimumab that have been observed in some cases, which is projected to hamper the market growth. However, the high cost of Adalimumab is acting as a major challenge for the growth of the Adalimumab Market during the forecast period 2020-2025. 

Adalimumab Market Industry outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Adalimumab Market. Key companies of this market Croda International Plc, Clariant AG, AkzoNobel N.V, Ashland Inc, Evonik Industries, PolyOne Corporation, DuPont, Addcomp Holland, Lonza Group, and PCC Chemax Inc.

Acquisitions/Product Launches:

  • In August 2020, Cadila Pharmaceuticals has announced the launch of its adalimumab biosimilar, Cadalimab, referencing AbbVie's Humira, in India
  • In May 2019, AbbVie has announced that it has settled its patent litigation with Boehringer Ingelheim over adalimumab. It is an important settlement as it resolves all the Humira-related patent litigation in the US and provides access for another biosimilar manufacturer seeking to enter the US.

1. Adalimumab Market - Overview
    1.1 Definitions and Scope
2. Adalimumab Market - Executive Summary
    2.1 Market Revenue, Market Size and Key Trends
    2.2 Key trends by Type
    2.3 Key trends by Disease
    2.4 Key trends by End User
    2.5 Key trends by Geography
3. Adalimumab Market– Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies 
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Adalimumab Market- Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Adalimumab Market– Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Adalimumab Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Adalimumab Market– Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Adalimumab Market- By Type (Market Size - $Million/$Billion)
    8.1 Adalimumab
    8.2 Adalimumab Biosimilar
9. Adalimumab Market– By Disease (Market Size – $Million/$Billion)
    9.1 Crohn’s disease
    9.2 Psoriatic arthritis
    9.3 Rheumatoid arthritis
    9.4 Ulcerative colitis
    9.5 Others
10. Adalimumab Market– By End User (Market Size – $Million/$Billion)
    10.1 Hospitals
    10.2 Specialty Clinics
    10.3 Others
11. Adalimumab Market- By Geography (Market Size – $Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Adalimumab Market- Entropy
13. Adalimumab Market– Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Adalimumab Market– Key Company List by Country Premium Premium
15. Adalimumab Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
List of Tables

Table 1: Adalimumab Market Overview 2021-2026
Table 2: Adalimumab Market Leader Analysis 2018-2019 (US$)
Table 3: Adalimumab Market Product Analysis 2018-2019 (US$)
Table 4: Adalimumab Market End User Analysis 2018-2019 (US$)
Table 5: Adalimumab Market Patent Analysis 2013-2018* (US$)
Table 6: Adalimumab Market Financial Analysis 2018-2019 (US$)
Table 7: Adalimumab Market Driver Analysis 2018-2019 (US$)
Table 8: Adalimumab Market Challenges Analysis 2018-2019 (US$)
Table 9: Adalimumab Market Constraint Analysis 2018-2019 (US$)
Table 10: Adalimumab Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Adalimumab Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Adalimumab Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Adalimumab Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Adalimumab Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Adalimumab Market Value Chain Analysis 2018-2019 (US$)
Table 16: Adalimumab Market Pricing Analysis 2021-2026 (US$)
Table 17: Adalimumab Market Opportunities Analysis 2021-2026 (US$)
Table 18: Adalimumab Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Adalimumab Market Supplier Analysis 2018-2019 (US$)
Table 20: Adalimumab Market Distributor Analysis 2018-2019 (US$)
Table 21: Adalimumab Market Trend Analysis 2018-2019 (US$)
Table 22: Adalimumab Market Size 2018 (US$)
Table 23: Adalimumab Market Forecast Analysis 2021-2026 (US$)
Table 24: Adalimumab Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 26: Adalimumab Market By Application, Revenue & Volume,By Rheumatoid Arthritis, 2021-2026 ($)
Table 27: Adalimumab Market By Application, Revenue & Volume,By Psoriasis, 2021-2026 ($)
Table 28: Adalimumab Market By Application, Revenue & Volume,By Chron’s Disease, 2021-2026 ($)
Table 29: Adalimumab Market By Application, Revenue & Volume,By Ulcerative Colitis, 2021-2026 ($)
Table 30: North America Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 31: South america Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 32: Europe Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 33: APAC Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 34: Middle East & Africa Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 35: Russia Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 36: Israel Adalimumab Market, Revenue & Volume,By Application, 2021-2026 ($)
Table 37: Top Companies 2018 (US$) Adalimumab Market, Revenue & Volume
Table 38: Product Launch 2018-2019 Adalimumab Market, Revenue & Volume
Table 39: Mergers & Acquistions 2018-2019 Adalimumab Market, Revenue & Volume


List of Figures
Figure 1: Overview of Adalimumab Market 2021-2026
Figure 2: Market Share Analysis for Adalimumab Market 2018 (US$)
Figure 3: Product Comparison in Adalimumab Market 2018-2019 (US$)
Figure 4: End User Profile for Adalimumab Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Adalimumab Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Adalimumab Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Adalimumab Market 2018-2019
Figure 8: Ecosystem Analysis in Adalimumab Market 2018
Figure 9: Average Selling Price in Adalimumab Market 2021-2026
Figure 10: Top Opportunites in Adalimumab Market 2018-2019
Figure 11: Market Life Cycle Analysis in Adalimumab Market
Figure 12: GlobalBy ApplicationAdalimumab Market Revenue, 2021-2026 ($)
Figure 13: Global Adalimumab Market - By Geography
Figure 14: Global Adalimumab Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 15: Global Adalimumab Market CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 17: US Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 30: Brazil Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 59: U.K Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 92: China Adalimumab Market Value & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Adalimumab Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Adalimumab Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Adalimumab Market Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Adalimumab Market 
Figure 130: Developments, 2018-2019*Adalimumab Market 
Figure 131: Company 1 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Adalimumab Market Net Sales Share, By Geography, 2018 (%)